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Personalized medicine holds great promise for improving disease diagnosis and therapy through the customization 
of treatment based on a patient’s specific needs. 1-3 Diabetes is 
one disease for which this approach is of potential interest. 4-7 
The number of diabetic patients has increased by 90% over the 
last 20 years, with an estimated 26 million individuals in the 
U.S. suffering from this disease. 4, 5
Some of the complications of diabetes are associated with 
the nonenzymatic glycation of proteins. 8 Glycation begins 
when a free amine group on a protein reacts with an aldehyde 
group on a reducing sugar (e.g., glucose) to form a reversible 
Schiff base, which can later rearrange to produce a more sta-
ble fructosamine residue, or Amadori product. 9-11 Numerous 
studies have indicated that glycation can produce structural 
and functional modifications in proteins with long half-lives 
(e.g., collagen, lens crystalline, and hemoglobin). 12, 13 Recent 
research has also examined the effects of glycation on human 
serum albumin (HSA), the main protein in serum and an im-
portant binding agent for transporting many drugs and endog-
enous compounds in the circulatory system. 14-19
The binding of drugs to HSA usually occurs at Sudlow 
sites I and II, which are located in subdomains IIA and IIIA 
of this protein. 20 It has been suggested that the binding of 
HSA to some drugs can be altered by glycation-related mod-
ifications that occur in the vicinity of Sudlow sites I and II. 16, 
18 A group of drugs that may exhibit such changes are the sul-
fonylureas, which have been used to treat type II diabetes for 
over 50 years. 21 These drugs are highly bound (i.e., 90–99%) 
to serum proteins and particularly to HSA. 22 Displacement 
or release of these drugs from serum proteins is known to 
cause hypoglycemia, 23 while the presence of an effective dose 
that is too low for the same drugs may result in elevated glu-
cose levels.
In previous studies, high-performance affinity chromatog-
raphy (HPAC) has been used to examine the interactions be-
tween several first- and second-generation sulfonylurea drugs 
with normal and in vitro glycated HSA. 24-27 The use of HPAC 
over conventional methods for monitoring drug–protein bind-
ing (e.g., ultrafiltration and equilibrium dialysis) has several 
benefits, such as the high reproducibility of this method plus 
its good precision and ease of automation. Other advantages 
include the small sample requirements of HPAC and its abil-
ity to reuse the same protein preparation for hundreds of ex-
periments. 28, 29
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Abstract
This report used high-performance affinity microcolumns to 
examine the changes in binding by sulfonylurea drugs to in 
vivo glycated HSA that had been isolated from individual pa-
tients with diabetes. An immunoextraction approach was de-
veloped to isolate HSA and glycated HSA from clinical samples, 
using only 20 μL of plasma or serum and 6–12 nmol of pro-
tein to prepare each affinity microcolumn. It was found that 
the affinity microcolumns could be used in either frontal anal-
ysis or zonal elution studies, which typically required only 4–8 
min per run. The microcolumns had good stability and allowed 
data to be obtained for multiple drugs and experimental con-
ditions over hundreds of sample application cycles. Both the
overall binding, as measured by frontal analysis, and site-specific interactions, as examined by zonal elution, showed 
good agreement with previous data that had been obtained for in vitro glycated HSA with similar levels of modification. 
It was also possible to directly compare the changes in site-specific binding that occurred between sulfonylurea drugs 
or as the level of HSA glycation was varied. This method is not limited to clinical samples of glycated HSA but could be 
adapted for work with other modified proteins of interest in personalized medicine.
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In this report, HPAC will be explored for use in studying 
drug interactions with in vivo glycated HSA that has been iso-
lated from individuals known to have diabetes. Initial studies 
will examine the use of immunoextraction columns for isolat-
ing in vivo glycated HSA from small amounts of samples ob-
tained from patients and will combine this approach with re-
cent developments in the preparation of affinity microcolumns 
for drug–protein binding studies. 28, 30 The resulting affin-
ity microcolumns will then be used to look at the overall bind-
ing of several sulfonylurea drugs to in vivo glycated HSA, as 
will be studied by frontal analysis. The same columns will be 
employed with zonal elution to detect any changes in binding 
that might occur for the tested drugs at Sudlow sites I and II 
upon the in vivo glycation of HSA in individual patients. The 
results should provide information that can be used to better 
understand these interactions and should lead to new analyti-
cal tools that can be employed in personalized medicine for pa-
tients with diabetes or other diseases.
Experimental Section
Materials and Reagents. The following solutes were 
purchased from Sigma-Aldrich (St. Louis, MO): acetohex-
amide (99% pure), tolbutamide (99.8%), gliclazide (99.5%), 
R-warfarin (>99%), and l-tryptophan (>99%). A commer-
cial sample of serum made from male AB plasma was also ob-
tained from Sigma-Aldrich (product H4522, lot 039K0728; 
prescreened and found to be negative for HIV-1/HIV-2, hep-
atitis B and hepatitis C). The Nucleosil Si-300 (particle size, 7 
μm; pore size, 300 Å) was from Macherey-Nagel (Düren, Ger-
many). Reagents for the bicinchoninic acid (BCA) protein as-
say, as used for determining the protein content of the isolated 
glycated HSA samples and chromatographic supports, were 
from Pierce (Rockford, IL). The measurement of glycation lev-
els was conducted by using a fructosamine assay kit from Dia-
zyme Laboratories (San Diego, CA), as described previously. 25 
The Vivapure anti-HSA resin was from Sartorius Stedim Bio-
tech (Göttingen, Germany). All buffers and aqueous solutions 
were prepared using water from a Nanopure system (Barn-
stead, Dubuque, IA) and were filtered using 0.2 μm GNWP ny-
lon filters from Millipore (Billerica, MA).
Apparatus. The isolation of HSA and glycated HSA from 
serum or plasma was performed using a 5702RH tempera-
ture-controlled centrifuge from Eppendorf (New York, NY) 
and a fixed-angle centrifuge rotor from VWR (West Chester, 
PA). The chromatographic experiments were carried out by us-
ing a Jasco 2000 HPLC system (Easton, MD) that contained 
a DG-2080–53 three solvent degasser, two PU-2080 isocratic 
pumps, an AS-2057 autosampler equipped with a 100 μL sam-
ple loop (operated in the partial loop injection mode), and a 
UV-2075 absorbance detector. The columns were kept at 37 °C 
by using a Jasco CO-2060 column oven. A Rheodyne Advan-
tage PF six-port switching valve (Cotati, CA) was used for al-
ternating the passage of drug and buffer solutions through the 
columns during the frontal analysis studies. The system com-
ponents were controlled by a Jasco LC-Net II/ADC system and 
EZChrom Elite software v3.2.1 (Scientific Software, Pleasan-
ton, CA). The breakthrough times for the frontal analysis data 
and central peak moments for the zonal elution data were de-
termined by using PeakFit 4.12 (SeaSolve Software, San Jose, 
CA). Linear and nonlinear regression were conducted by utiliz-
ing DataFit 8.1.69 (Oakdale Engineering, PA).
Sample Pretreatment and Column Preparation. 
Pre-existing EDTA plasma samples, acquired through veni-
puncture and generated according to standard procedures for 
work with whole blood (see Supporting Information), were ob-
tained from deidentified patients known to have diabetes, as 
provided by W. Clarke at the Johns Hopkins University School 
of Medicine. The collection and provision of these samples was 
performed with approval of the Johns Hopkins Institutional 
Review Board. All of these samples were handled with appro-
priate precautions for materials that may contain bloodborne 
pathogens. The level of hemoglobin A1c (HbA1c) was mea-
sured and provided for each plasma sample, as is used in clini-
cal laboratories for the diagnosis and long-term monitoring of 
glucose control in diabetic patients. 31-35
Figure 1 shows the general procedure that was used to iso-
late HSA and in vivo glycated HSA from serum or plasma sam-
ples. This procedure was conducted by using a 20 μL serum or 
plasma sample. In this study, such a sample was used as a rep-
resentative portion of 1–2 mL of remnant EDTA plasma that 
was acquired for an individual patient; in future work, finger 
stick samples might also be employed, as are commonly used 
in routine glucose monitoring. The 20 μL of serum or plasma 
was added to a Vivaspin 6 spin-filter column that contained a 
fresh 400 μL portion of a 50% packed resin slurry with poly-
clonal anti-HSA antibody fragments immobilized onto cross-
linked agarose beads. Further details on the procedure for this 
isolation step, including the sample loading and elution condi-
tions, are provided in the Supporting Information and Results 
and Discussion.
Nucleosil Si-300 silica was converted into a diol-bonded 
form. 36 One portion of this support was used to immobi-
lize HSA/glycated HSA by the Schiff base method, 37 while a 
second portion was used to make a control support to which 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Scheme for the purification of human serum albu-
min (HSA) and in vivo glycated HSA from serum or plasma, 
as used prior to the immobilization of these proteins in affin-
ity microcolumns. More details are provided in the Support-
ing Information.
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no protein was added during the immobilization step. Each 
HSA/glycated HSA support and control support was down-
ward slurry-packed at 24 MPa (3500 psi) into a separate 2.0 
cm × 2.1 mm I.D. stainless steel column using pH 7.4, 0.067 M 
potassium phosphate buffer as the packing solution and was 
stored in this buffer at 4 °C when not in use. A BCA assay was 
performed to determine the protein content of each support, 
using normal HSA or in vitro glycated HSA as the standard 
and the control support as the blank. 25, 38
Chromatographic Studies. All chromatographic ex-
periments were conducted at 37 °C and using pH 7.4, 0.067 
M potassium phosphate buffer as the mobile phase. All drug 
and solute solutions were prepared in this mobile phase and 
filtered through a 0.2 μm nylon filter, followed by a 15 min de-
gassing step, prior to use. The solutions and samples of the 
sulfonylurea drugs and R-warfarin were used within two weeks 
of preparation. 24-27, 39, 40 The l-tryptophan solutions were pre-
pared fresh daily in the pH 7.4 buffer. 40 The samples were ap-
plied or injected at a typical flow rate of 0.5 mL/min, as shown 
in prior work to give reproducible retention factors and bind-
ing capacities for these drugs and solutes on similar HSA col-
umns. 24-27, 39, 40
In the frontal analysis studies, each column was first equili-
brated with the pH 7.4 mobile phase buffer. The mobile phase 
was then switched to a solution that contained a known con-
centration of the desired drug in the same buffer. These solu-
tions included up to sixteen concentrations of acetohexamide 
that ranged from 1 to 1000 μM and ten concentrations of gli-
clazide or tolbutamide that ranged from 1 to 200 μM. These 
conditions included the typical therapeutic levels for these 
drugs and provided a sufficiently broad range of conditions to 
allow the observation of both weak and moderate-to-high af-
finity interactions of these solutes with glycated HSA. 24-27, 41 
Each drug solution was continuously applied to the column 
until a breakthrough curve with a level plateau was produced. 
The system was later switched back to the pH 7.4, 0.067 M 
phosphate buffer to elute the retained analyte from the column 
under isocratic conditions. This process was repeated three 
times at each concentration for all drugs on the test columns 
and control column.
To keep the absorbance values within the linear range of 
the detector, the breakthrough curves for acetohexamide were 
monitored at 248 nm for concentrations of 1–20 μM and at 315 
nm for concentrations of 30–1000 μM. Gliclazide and tolbuta-
mide were monitored at 248 nm for all of the concentrations 
used in frontal analysis. The central location of each break-
through curve was determined by using a Savitzky-Golay first 
derivative algorithm for smoothing, followed by fitting of the 
first derivative to an exponentially modified Gaussian curve. 
A correction for any nonspecific binding of a drug to the sup-
port was made by subtracting the breakthrough times of the 
control column from those obtained on the test column at each 
drug concentration, as described previously for the same an-
alytes on columns based on normal HSA or in vitro glycated 
HSA. 24-27, 39, 40
Zonal elution studies were performed by using R-warfarin 
and l-tryptophan as site-specific probes for Sudlow sites I and 
II of HSA. 24-27, 39, 40 The pH 7.4 mobile phase was used to pre-
pare all of the injected samples and competing agents for these 
experiments. The acetohexamide, gliclazide, or tolbutamide 
solutions ranged in concentration from 0 to 20 μM. The sam-
ples consisted of 20 μL injections of 5 μM R-warfarin or 5 μM 
l-tryptophan that were prepared by diluting each probe with a 
mobile phase that contained the final desired concentration of 
the competing agent. Elution of the injected solutes was mon-
itored at 308 nm for R-warfarin and at 280 nm for l-trypto-
phan. Nonspecific binding was evaluated and corrected by in-
jecting all of the samples onto a control column. To determine 
the void time of each column, 20 μL injections of 20 μM so-
dium nitrate were made (i.e., a nonretained solute on HSA col-
umns), and the resulting peak was monitored at 205 nm. The 
central moment of each peak was determined by using a fit to 
an exponentially modified Gaussian curve. 39
Results and Discussion
Isolation of HSA and Glycated HSA. Immunoex-
traction based on polyclonal anti-HSA antibodies was used to 
isolate HSA and glycated HSA from serum or EDTA plasma. 
This was conducted by using a commercial anti-HSA sup-
port with a binding capacity of at least 2 mg of HSA/mL resin. 
The extraction efficiency of this approach was tested by com-
bining a fresh 400 μL portion of the immunoaffinity support 
with a 20 μL standard sample that contained 800 μg of HSA or 
40 g/L HSA (i.e., a representative concentration for this pro-
tein in serum or plasma). 41 This sample was applied to the 
support in pH 7.4, 0.10 M Tris buffer, which was also added 
in a 200 μL portion to wash away nonretained sample com-
ponents. Two 200 μL portions of pH 2.8, 0.10 M glycine–HCl 
buffer were then added to elute the retained protein, as rec-
ommended by the manufacturer. A fresh portion of the immu-
noaffinity resin was then used for the next sample application, 
thus avoiding the need for column regeneration and providing 
stable antibodies with a high and consistent level of binding. 
However, regeneration and reuse of such a resin could also 
have been employed, as has been described for other anti-HSA 
columns. 42, 43
Only 54% of the applied HSA was recovered by the ini-
tial immunoextraction approach, in agreement with prior ob-
servations made under similar conditions with the same type 
of anti-HSA resin. 44 As the number of elution steps was in-
creased from two to six, the recovery of HSA increased to 90%. 
A recovery of at least 90% and approaching 100% was also 
noted when this study was repeated for samples that contained 
highly glycated HSA that was previously prepared in vitro with 
a level of modification of 3.35 (±0.14) mol hexose/mol pro-
tein. 25 A high level of recovery was not essential to the bind-
ing studies that were later carried out with the final affinity 
microcolumns, as long as a representative portion of the origi-
nal protein population had been captured; however, a high re-
covery did reduce the sample volume that was needed to pre-
pare the affinity microcolumns. The specificity of the modified 
purification approach was examined by using it with a 20 μL 
commercial sample of human serum known to contain 1020 
μg protein and 840 μg HSA. The retained and isolated protein 
fraction showed only one detectable band by SDS-PAGE which 
matched that of an HSA standard, in agreement with previous 
work using this support. 44-46
A number of buffer combinations were tested with the im-
munoextraction method to obtain a high recovery for HSA and 
glycated HSA while avoiding long-term changes in the activi-
ties of these proteins. In these experiments, 20 μL of 40 mg/
mL HSA or highly glycated HSA was incubated at room tem-
perature for 20 min with 200 μL of 0.10 M glycine-HCl buf-
fer that had a pH of 2.8 to 4.0. This incubation step was fol-
lowed by neutralization of the solution to a pH of 7.0–7.4 by 
adding 10 μL of pH 8.0, 1.0 M Tris buffer. A binding study 
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based on ultrafiltration, as described in the Supporting Infor-
mation and using tolbutamide, was then carried out with (1) 
the treated protein samples and (2) control samples that had 
the same final concentrations of drug and HSA/glycated HSA 
but that were placed directly into pH 7.4, 0.10 M Tris buffer. In 
each case, the controls and treated samples had no significant 
difference in their binding at the 95% confidence level. The ef-
fect of the elution pH on protein recovery was also considered. 
A decrease in the recovery of HSA from over 90% to 25% was 
observed when increasing the elution pH from 2.8 to 3.5. On 
the basis of these results, an approach using an elution pH of 
2.8 was used in all later experiments involving immunoextrac-
tion for the isolation of in vivo glycated HSA.
Preparation of Affinity Microcolumns Using 
Clinical Samples. The scheme optimized in the previous 
section was next used to isolate glycated HSA from individ-
ual clinical samples. This was of interest because recent stud-
ies have found that there are differences in the binding of sul-
fonylurea drugs to samples of normal HSA, as prepared from 
pooled serum, versus in vitro glycated HSA that has various 
levels of glycation. 24-27 However, it is not yet known whether 
changes with glycation also occur for these drugs with HSA 
that has been glycated in vivo. Also, no known previous stud-
ies have examined the creation of affinity columns for binding 
studies that have used HSA or other proteins from specific in-
dividuals. 28, 29 Work in this section sought to develop tools for 
obtaining such information by creating affinity microcolumns 
that were prepared by using in vivo glycated HSA from indi-
vidual patients.
To explore this approach, microcolumns were prepared us-
ing two different preparations of in vivo glycated HSA. The 
first clinical sample, glycated HSA-CS1, was from a diabetic 
patient who had an HbA1c level of 10.0%, which represented 
an estimated long-term glucose level of 15.5 mM in blood 47 
(Note: An HbA1c value of ≥6.5% is often used to indicate the 
presence of diabetes in a patient). 33-35 The second sample, gly-
cated HSA-CS2, came from a patient who had an HbA1c level 
of 13.7%, which represented a case of uncontrolled and/or ad-
vanced diabetes and an estimated long-term glucose level of 
22.8 mM. 47 The measured levels of glycation were 1.19 (±0.15) 
and 1.51 (±0.20) mol hexose/mol HSA for the isolated sam-
ples of HSA-CS1 and HSA-CS2. The results obtained for these 
columns were also compared to those obtained previously for 
normal HSA that was obtained from pooled human serum. 24
The column size that was used with these samples was 2.0 
cm × 2.1 mm I.D. It was known from previous work with nor-
mal HSA that this size was suitable for use in drug binding 
studies and offered good precision along with reasonably fast 
analysis times. It was also known from prior work that a col-
umn of this size could contain roughly 1 mg of immobilized 
HSA when using the same type of silica as employed in this re-
port. 24 This amount of HSA corresponded to what is found in 
approximately 20–28 μL of human serum or plasma. 41 When 
the isolated in vivo glycated HSA was immobilized by the 
Schiff base method, the final supports contained 26 (±1) mg 
protein/g silica for glycated HSA-CS1 and 14 (±1) mg protein/g 
silica for glycated HSA-CS2. These results represented a total 
protein content of 0.4–0.8 mg or 6–12 nmol (3.6–7.2 × 1015 
molecules) in the 2.0 cm × 2.1 mm I.D. columns. Previous 
work with in vitro glycated HSA and the same column size has 
found good agreement with binding parameters that have been 
obtained using much larger amounts of protein in ultrafiltra-
tion studies, 25, 27 indicating that the amount of protein in these 
microcolumns was sufficient to provide a good representation 
of the glycated HSA populations and their binding properties 
in the original clinical samples.
Frontal Analysis Studies for Clinical Samples. 
The columns containing in vivo glycated HSA were examined 
by frontal analysis to study their overall binding to various sul-
fonylurea drugs. Each frontal analysis experiment took roughly 
6–8 min to complete at 0.5 mL/min on a 2.0 cm × 2.1 mm I.D. 
microcolumn (see Supporting Information for examples). This 
meant that even triplicate experiments over a wide range of 
concentrations could be carried out in a reasonable amount of 
time. Each of the in vivo glycated HSA columns was used over 
the course of approximately 9–12 months and at least 250 sam-
ple application cycles for the work described in this report. 
The stability of these columns was monitored by examining 
their retention for R-warfarin and l-tryptophan, as determined 
through the site-specific competitive studies that are described 
later for these same columns. During the entire period of this 
study, the maximum variation in the retention factor for R-
warfarin was 13–31%, and the maximum variation in the reten-
tion factor for l-tryptophan was 3–22%; changes of less than 
5–11% and 1–3%, respectively, were noted in these same pa-
rameters over the first 2–3 months of column operation. This 
level of variation did not create any problems during the analy-
sis of data from the frontal analysis experiments, as illustrated 
by Figure 2 and Equation 1, which provided association equilib-
rium constants that were determined independently from the 
column binding capacity. 28 This feature also meant it was not 
necessary to capture all of the glycated HSA/HSA from a sam-
ple or to have the same amount of protein in each microcolumn 
for these measurements, as long as a representative portion of 
the original protein population was present.
Figure 2. Fit of frontal analysis data obtained for acetohex-
amide on the glycated HSA-CS1 column when using a two-
site binding model, as described by Equation 1. 25 Each data 
point represents the average of three measurements for 
mLapp, the moles of analyte required to reach the mean point 
of the breakthrough curve at a given molar concentration 
of the applied analyte. The error bars represent ±1 SD for 
this value and ranged in size from ±0.01–5.5% (average, ± 
1.1%). Terms: molar concentration of applied analyte A, [A]; 
Ka1 and Ka2, association equilibrium constants for the analyte 
at binding sites 1 and 2; mL1 and mL2, total moles of binding 
sites 1 and 2 in the column.
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The frontal analysis data were analyzed by preparing a 
graph of the moles of applied analyte that were required to 
reach the central point of the breakthrough curve versus the 
concentration of analyte that was applied to the column. An 
example of such a plot is shown in Figure 2. These data were 
fit to various binding models. The results for acetohexamide in 
Figure 2 had the best-fit to the two-site model in Equation 1, 
with a correlation coefficient of 0.993 (n = 16) and only ran-
dom variations in the corresponding residual plot. Fitting the 
same data to a one-site model (see Supporting Information) 
gave a lower correlation coefficient of 0.967 and nonrandom 
variations in a residual plot. No further improvement in the fit 
was obtained when using a three-site model. Similar results 
were obtained for acetohexamide on the glycated HSA-CS2 
column and for tolbutamide and gliclazide with both microcol-
umns containing in vivo glycated HSA (i.e., correlation coeffi-
cients of 0.999 for the two-site model versus 0.949–0.997 for 
the one-site model at n = 10–16). The best fit noted to a two-
site binding model is consistent with previous results reported 
for the same drugs on columns that contained normal HSA or 
in vitro glycated HSA. 24-27 Table 1 summarizes the equilibrium 
constants and moles of binding sites that were estimated with 
the two-site model for the sulfonylurea drugs on the in vivo 
glycated HSA columns. Previous values obtained for normal 
HSA are also provided for reference. 24, 27
The two classes of sites taking part in these interactions 
consisted of relatively high affinity interactions involving 1–2 
binding regions (i.e., as estimated based on the specific activ-
ities in Table 1) and a group of lower affinity sites involving 
up to 3–5 regions on HSA. These results were consistent with 
those reported for the same drugs with normal HSA or in vi-
tro glycated HSA. 24-27 The apparent association equilibrium 
constants that were estimated for the group of high affinity re-
gions had relative standard deviations of ±7.1 to ±38% (aver-
age, ± 18%) and were in the general range of 0.65–1.4 × 105 
M–1. This range was consistent with earlier values reported 
for the same drugs with in vitro glycated HSA that had simi-
lar or slightly lower levels of glycation (i.e., binding constants 
of 0.84–1.2 × 105 M–1 for tolbutamide, 1.0 × 105 M–1 for glicla-
zide, and 1.2–2.0 × 105 M–1 for acetohexamide). 25-27
Site-Specific Competition Studies for Clinical 
Samples. The next set of studies used zonal elution and com-
petition studies with site-specific probe compounds to explore 
the high affinity regions on in vivo glycated HSA that were inter-
acting with the sulfonylurea drugs. A representative set of chro-
matograms for these studies is provided in the Supporting Infor-
mation. These experiments typically required 4–7 min per run, 
which again made it easy to employ the microcolumns for repli-
cate studies with various drugs and experimental conditions. As 
noted earlier, the in vivo glycated HSA columns had good stabil-
ity and showed only relatively small changes in their retention 
factors for R-warfarin and l-tryptophan during the course of 
these studies. In addition, the approach that was used to analyze 
the zonal elution data, as illustrated in Figure 3 and Equation 
2, provided association equilibrium constants that were deter-
mined in a manner that was independent of any modest varia-
tions that occurred in the column binding capacity. 28 This fact 
again meant that only a representative portion of the glycated 
HSA/HSA from a sample was needed for this type of study and 
that this method could be used even when there were moder-
ate differences in the amounts of protein in the affinity micro-
columns that were prepared from different samples.
Competition studies at Sudlow site I were conducted by us-
ing R-warfarin as a site-specific probe. 20, 24, 28, 29 Figure 3a 
gives examples of the resulting plots of 1/k versus the mobile 
phase concentration of the tested drug, as prepared according 
to Equation 2. These plots gave linear relationships for all of 
the sulfonylurea drugs and in vivo glycated HSA columns, with 
correlation coefficients of 0.951–0.990 (n = 6–7) and only 
random variations in the data points about the best-fit lines. 
These results were consistent with a model in which the sulfo-
nylurea drugs had binding and direct competition with R-war-
farin at Sudlow site I. Similar behavior has been noted for col-
umns containing normal HSA or in vitro glycated HSA. 24-27
The best-fit lines for plots like those in Figure 3a were 
used to obtain the association equilibrium constant for each 
Table 1. Binding Parameters Obtained by Frontal Analysis and Using a Two-Site Model to Describe the Interac-
tions of Various Sulfonylurea Drugs with Columns Containing Normal HSA or in vivo Glycated HSAa
  high affinity sites lower affinity sites
column/drug Ka1(×105 M–1) mL1(×10–8 M–1) relative activity  Ka2(×103 M–1) mL2(×10–8 M–1) relative activity  
   (mol/mol HSA)    (mol/mol HSA)
normal HSAb
tolbutamide 0.87 (±0.06) 2.0 (±0.1) 1.12 (±0.08) 8.1 (±1.7) 1.8 (±0.1) 1.01 (±0.08)
gliclazide 0.71 (±0.19) 0.71 (±0.22) 0.50 (±0.16) 8.9 (±1.5) 2.7 (±0.1) 1.9 (±0.2)
acetohexamide 1.3 (±0.2) 2.4 (±0.1) 1.3 (±0.1) 0.35 (±0.30) 9.3 (±5.5) 5.2 (±3.1)
glycated HSA-CS1
tolbutamidec 0.97 (±0.12) 1.2 (±0.2) 0.96 (±0.22) 5.7 (±2.2) 1.2 (±0.3) 1.0 (±0.2)
gliclazide 0.65 (±0.25) 0.55 (±0.27) 0.45 (±0.22) 11 (±3.0) 1.6 (±0.2) 1.3 (±0.2)
acetohexamide 1.0 (±0.1) 1.6 (±0.1) 1.3 (±0.1) 1.2 (±0.9) 1.7 (±0.5) 1.4 (±0.4)
glycated HSA-CS2
tolbutamide 0.91 (±0.19) 0.80 (±0.17) 1.2 (±0.25) 10 (±5) 0.71 (±0.16) 1.04 (±0.17)
gliclazide 0.77 (±0.13) 0.38 (±0.06) 0.56 (±0.09) 5.0 (±0.9) 1.4 (±0.1) 2.08 (±0.09)
acetohexamide 1.4 (±0.1) 0.86 (±0.03) 1.3 (±0.1) 1.0 (±0.3) 2.2 (±0.3) 3.2 (±0.5)
a. All of these data were obtained at pH 7.4 and 37 °C. The values in parentheses represent a range of ±1 SD, as obtained through nonlinear re-
gression for the best-fit parameters to Equation 1 to the group of results (n = 10–16, each measured in triplicate) or through error propagation 
based on the standard deviations for these parameters.
b. The values provided for acetohexamide or tolbutamide and gliclazide with normal HSA are given for reference and were also measured by 
HPAC. These results were obtained from References 24 and 27.
c. The Ka1 and mL1 values for tolbutamide with glycated HSA-CS1 were estimated from the linear region of a double reciprocal plot made accord-
ing to Reference 24.
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sulfonylurea drug at Sudlow site I on the samples of in vivo 
glycated HSA (see Table 2), giving values that had relative 
standard deviations ranging from ±5.1 to ±10.0% (average, ± 
7.4%). These equilibrium constants were in the range expected 
for one of the high affinity regions of these drugs on HSA and 
showed good agreement with previous values of 6.5–6.9 × 104 
M–1 for tolbutamide, 1.8–3.6 × 104 M–1 for gliclazide, and 3.8–
5.9 × 104 M–1 for acetohexamide that have been measured at 
the same site when using in vitro glycated HSA with similar or 
slightly lower levels of glycation. 25-27
As has been noted in prior work with in vitro glycated 
HSA, 25-27 the strength of these interactions and the change in 
these interactions with the extent of glycation differed between 
the drugs that were tested. For instance, the association equilib-
rium constant for tolbutamide at Sudlow site I increased by 1.2- 
to 1.4-fold in going from normal HSA to both samples of in vivo 
glycated HSA. These shifts in affinity, as well as the 1.2-fold in-
crease in binding strength seen for tolbutamide in going from 
glycated HSA-CS1 to glycated HSA-CS2, were all significant at 
the 95% confidence level. (Note: The same confidence level was 
used in all further comparisons in this study.) For gliclazide, 
an increase of 1.2-fold or a decrease of 0.74-fold in affinity oc-
curred when comparing normal HSA with glycated HSA-CS1 or 
glycated HSA-CS2. A small increase of 1.1-fold or a decrease of 
0.95-fold in affinity may have been present for acetohexamide 
in going from normal HSA to glycated HSA-CS1 or glycated 
HSA-CS2, but these differences were not statistically significant. 
In addition, a 0.61-fold decrease in affinity was noted for glicla-
zide between glycated HSA-CS1 and glycated HSA-CS2.
It has been suggested that changes in binding like those 
seen in Table 2 may be produced by variations in the extent 
and types of modifications that occur at various regions on 
HSA during the glycation process. 16, 18, 25-27 This is supported 
by the fact that such modifications have been previously noted 
to occur at or near Sudlow sites I and II for both in vivo gly-
cated HSA and in vitro glycated HSA, 48-50 with the latter being 
prepared under the same or similar conditions to those used 
for the binding studies in refs 25−27. The shifts in binding seen 
in Table 2 are consistent with the fact that glycation-related 
modifications at Sudlow sites I and II have also been found for 
samples of the in vivo glycated HSA that were used in this cur-
rent study (see Supporting Information). In addition, it has 
been observed with in vitro glycated HSA that the pattern of 
these modifications can vary with the level of glycation. 48, 49 
This explains why the affinity for a drug at individual binding 
sites may change between normal HSA and glycated HSA or 
between two different preparations of glycated HSA, 25-27 as is 
illustrated in Table 2.
Additional competition studies were carried out by using 
l-tryptophan as a probe for Sudlow site II, 20, 24, 28, 29 as illus-
trated in Figure 3b. Plots prepared according to Equation 2 
gave linear behavior for all the sulfonylureas tested, indicat-
ing that these drugs had binding and direct competition with 
l-tryptophan at Sudlow site II. The correlation coefficients for 
these graphs ranged from 0.975 to 0.999 (n = 6–7) and gave 
only random variations in the data points about the best-fit 
lines. These results agreed with data that have been obtained 
for the same drugs using columns that contained normal HSA 
or in vitro glycated HSA. 24-27
Figure 3. Change in the retention factor (k) at (a) Sudlow 
site I for R-warfarin in the presence of tolbutamide as a com-
peting agent and (b) at Sudlow site II for l-tryptophan in the 
presence of acetohexamide, as obtained for columns contain-
ing glycated HSA-CS1 (●) or glycated HSA-CS2 (■). The er-
ror bars represent ±1 SD for three replicate measurements 
of 1/k and are often comparable in size to the markers used 
in these plots, especially in (a). The size of these error bars 
ranged from (a) ± 0.08–0.93% (average, ± 0.24%) to (b) ± 
0.60–5.0% (average, ± 1.9%). Equation 2 represents the re-
lationship that is expected for a system with direct competi-
tion at a single type of binding site between the retention fac-
tor for the injected probe (A) and the molar concentration of 
the competing agent in the mobile phase, [I]. Terms: KaA and 
KaI, association equilibrium constants for the injected probe 
and competing agent, respectively, at their site of competi-
tion; VM, column void volume; mL, moles of common bind-
ing sites for A and I. On the basis of Equation 2, a plot of 1/k 
versus [I] should produce a linear relationship for a system 
with single-site competition, where the value of KaI can be 
found by taking the ratio of the slope over the intercept. 25.
Table 2. Association Equilibrium Constants (KaI) Measured 
at Sudlow Sites I and II for Various Sulfonylurea Drug with 
Normal HSA and in Vivo Glycated HSA
binding site                 KaI(×10
4 M–1)a
and column tolbutamide gliclazide acetohexamide
Sudlow site I
normal HSAb 5.5 (±0.2) 1.9 (±0.04) 4.2 (±0.4)
glycated HSA-CS1 6.8 (±0.5) 2.3 (±0.2) 4.7 (±0.3)
glycated HSA-CS2 7.9 (±0.4) 1.4 (±0.1) 4.0 (±0.4)
Sudlow site II
normal HSAb 5.3 (±0.2) 6.0 (±0.5) 13 (±1.0)
glycated HSA-CS1 7.3 (±0.5) 11 (±1.0) 13 (±0.2)
glycated HSA-CS2 7.9 (±0.3) 9.2 (±0.7) 17 (±0.4)
a. These binding parameters were calculated from data obtained at 
pH 7.4 and 37 °C using the best-fit lines generated according Equa-
tion 2. The values in parentheses represent a range of ±1 SD for 
the population of results (n = 6–7, each measured in triplicate) and 
were determined by using error propagation with the standard devi-
ations of the slopes and intercepts of the best-fit lines that were ob-
tained when using Equation 2.
b. The values provided for acetohexamide or tolbutamide and glicla-
zide with normal HSA were obtained from References 24 and 27.
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Table 2 shows the association equilibrium constants at Sud-
low site II that were calculated from plots like those in Figure 
3b. These values had relative standard deviations ranging from 
±1.5 to ±9.1% (average, ± 5.2%). These equilibrium constants 
were in the range expected for one of the high affinity regions 
on glycated HSA and were similar to values of 5.9–7.2 × 104 
M–1 for tolbutamide, 3.8–7.6 × 104 M–1 for gliclazide and 7.9–
12 × 104 M–1 for acetohexamide that have been measured pre-
viously at Sudlow site II with in vitro glycated HSA that had 
similar or lower levels of glycation. 25-27 In this current study, 
tolbutamide had a 1.4- to 1.5-fold increase in affinity at Sud-
low site II in going from normal HSA to glycated HSA-CS1 or 
glycated HSA-CS2. For gliclazide, an increase of 1.8- or 1.5-
fold was seen at the same binding region in going from normal 
HSA to glycated HSA-CS1 or glycated HSA-CS2, respectively. 
No apparent change was seen when comparing the binding 
of acetohexamide at this site on normal HSA versus glycated 
HSA-CS1; however, a 1.3-fold increase in affinity was noted 
when the binding of acetohexamide at Sudlow site II on either 
of these columns was compared with the affinity noted for gly-
cated HSA-CS2.
Conclusion
It was found that affinity microcolumns could be used as 
analytical tools to examine the binding of drugs to modified 
proteins from individual clinical samples. This approach was 
demonstrated by using it to investigate the binding of several 
sulfonylurea drugs to in vivo glycated HSA. Only 20 μL of se-
rum or plasma was needed to prepare each affinity microcol-
umn, which contained 6–12 nmol protein. These microcol-
umns could be used to conduct binding studies with typical 
run times of 4–8 min and were quite stable, making it possible 
to obtain good reproducibility and to reuse the same protein 
preparation for many studies. For instance, over the course of 
more than 250 sample application cycles on each microcol-
umn, the equivalent of only 25–50 pmol protein was needed 
per experiment.
These affinity microcolumns were utilized in several for-
mats to examine the binding of sulfonylurea drugs with in 
vivo glycated HSA that was obtained from individual pa-
tients. Frontal analysis was employed to investigate the over-
all binding of each sulfonylurea drug and indicated that these 
drugs gave the best-fit to a model involving a group of 1–2 
high affinity sites and a group of up to 3–5 lower affinity 
binding regions. The apparent association equilibrium con-
stants measured for the high affinity sites of the in vivo gly-
cated HSA were in the general range of 0.65–1.4 × 105 M–1, 
which agreed with values that have been reported for the 
same drugs with comparable preparations of in vitro glycated 
HSA. 25-27
Zonal elution was utilized to study the interactions that oc-
curred at specific binding sites on HSA. These experiments in-
dicated that both Sudlow sites I and II on the in vivo glycated 
HSA were binding to all of the tested drugs. The association 
equilibrium constants for these interactions were consistent 
with values expected for the high affinity sites of these drugs. 
These values also agreed with previous data obtained for these 
drugs at the same sites on in vitro glycated HSA with similar 
levels of modification. 25-27 All of these results confirmed that 
the in vivo glycated HSA columns could be used to study the 
binding of drugs to modified proteins in a disease, such as di-
abetes, and in comparing samples from separate patients. It 
was further possible to use the data from these columns to see 
how these interactions changed with the extent of glycation. In 
some cases, the change in affinity at a given site was as large 
as 1.8-fold in going from normal HSA to in vivo glycated HSA. 
This observation also agrees with previous results for the same 
drugs and similar preparations of in vitro glycated HSA, for 
which changes in affinity of up to 1.4- to 1.9-fold have been re-
ported. 25-27 It is possible that even larger shifts in binding may 
be observed in future work when this approach is applied to a 
larger number of clinical samples. These changes are of pos-
sible clinical importance in that they would be expected to al-
ter the displacement of these drugs by other agents and the 
amount of such a drug that is present in the nonbound protein 
form in serum or plasma. These effects, in turn, could change 
the effective dose of the drug in a patient and lead to undesir-
able effects such as hypoglycemia or poor control of glucose 
levels. 22, 23, 25-27
The methods that were described in this study for prepar-
ing and using affinity microcolumns in binding studies are 
not limited to individual clinical samples of glycated HSA but 
could be adapted for work with alternative proteins or mod-
ified proteins. Examples of other serum carrier proteins that 
should be amenable to this approach include α1-acid glyco-
protein and lipoproteins, both of which have been used in 
prior drug-binding studies by HPAC involving proteins pre-
pared from pooled serum 51-55 and which are known to vary in 
their composition or structure with disease state. 56-58 It is ex-
pected that the application of this method could also be ex-
panded to include proteins that have been modified through 
processes other than glycation (e.g., glycosylation or alter-
ations because of oxidative stress). 56-58 In the future, this 
method could be extended to systems such as cytosolic pro-
teins that bind to lipids, hormones, or drugs. 59-61 The main 
requirement in each of these cases is the use of an appropri-
ate immunoaffinity support or comparable protein isolation 
system, and a sufficient sample volume to isolate the desired 
protein for placement in an affinity microcolumn. Continued 
improvements in the design of affinity microcolumns, along 
with the development of better isolation and immobilization 
schemes for work with small amounts of proteins, should 
further assist in this research. The expected result is a set of 
powerful tools for binding studies that will be applicable for 
use in personalized medicine and in the study of various dis-
ease states, ranging from diabetes to cancer and autoimmune 
disorders. 56-61
Supporting Information. Additional material as de-
scribed in the body of the paper is available following the 
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Supporting Information 
Sample collection and pretreatment.  The initial clinical samples were collected 
according to standard protocols by venipuncture for the analysis of hemoglobin A1C 
(HbA1C) using a 5 mL EDTA plasma collection tube.  The anticoagulated whole blood 
was processed to give plasma by using centrifugation at 2000 × g for 10 min to separate 
the plasma from the cells.  After centrifugation, the plasma was removed from the tube.  
A 1-2 mL portion of de-identified and remnant EDTA plasma was set aside and frozen at 
–20ºC until shipment. The frozen specimens were placed on dry ice during shipping and 
were stored at -80ºC upon receipt and until further use. 
To isolate HSA and in vivo glycated HSA from plasma or control serum, 20 L of 
a plasma or serum sample was added to a Vivaspin 6 spin-filter column that contained a 
fresh 400 L portion of a 50% packed resin slurry with polyclonal anti-HSA antibody 
fragments immobilized onto cross-linked agarose beads.  The initial buffer in this slurry 
was given by the manufacturer as being a proprietary pH 7.0-7.5 Tris buffer with a low 
salt concentration.  The antibody-containing beads had a reported minimum binding 
capacity of 2 mg HSA/mL resin.  The sample/resin mixture was placed on a rotary shaker 
for 15 min at room temperature.  After this incubation step, the spin-filter column was 
centrifuged at 400  g for 2 min and washed with 200 L of pH 7.4, 0.1 M Tris buffer for 
1 min at 400  g.  This washing procedure was repeated two times to reduce non-specific 
binding of sample components to the resin.  To elute the retained HSA and glycated 
HSA, the spin-filter column was washed six times with 200 L of pH 2.8, 0.1 M 
glycine/HCl buffer for 2 min at 400  g, with the collected HSA/glycated HSA fractions 
being pooled.  Immediately after each elution step, the collected fractions were adjusted 
to approximately pH 7.0 by adding pH 8.0, 1 M Tris buffer.  If additional HSA/glycated 
HSA was needed for other experiments (e.g., protein assays or mass spectrometry, as 
used in ongoing studies), this process was repeated for several cycles, each with a fresh 
spin-filter column, and the isolated proteins were pooled prior to use or further analysis. 
The collected HSA/glycated HSA for a given sample was placed into a sterile 
Slide-A-Lyzer dialysis cassette (10 kDa MW cutoff; 0.1–0.5 mL sample volume from 
Thermo Scientific, Rockford, IL) and dialyzed twice against two portions of 2.5 L water 
with gentle stirring for 2 h at room temperature.  The sample was dialyzed against water a 
third time without stirring at 4°C for 14–18 h, with the protein then being lyophilized and 
stored at -80°C for later use in immobilization or analysis (Note: An alternative 
procedure that can be used is to dialyze the sample against an appropriate buffer and then 
use the soluble protein directly for immobilization).  To determine if these isolation steps 
affected the activity of HSA, binding studies based on ultrafiltration, as described later in 
this section, were performed before and after representative samples of the control HSA 
and glycated HSA were treated with the low pH buffer, dialyzed and lyophilized. It was 
found that this process gave no significant changes, at the 95% confidence level, in the 
binding of HSA with the sulfonylurea drugs that were examined in this study. 
Ultrafiltration studies. Ultrafiltration was performed using Centrifree 
micropartition devices (30 kDa MW cutoff, 0.15–1.0 mL sample capacity) from Amicon 
(Danvers, MA, USA).  These devices were used along with a 5702RH temperature-
controlled centrifuge from Eppendorf (New York, NY) and a fixed-angle centrifuge rotor 
from VWR (West Chester, PA).  The flow-injection analysis experiments that were used 
to measure the drug content in each filtrate were carried out by using a Jasco 2000 HPLC 
system (Easton, MD, USA) that contained a DG-2080-53 three solvent degasser, two PU-
2080 isocratic pumps, an AS-2057 autosampler equipped with a 100 L sample loop 
(operated in the partial loop injection mode), and a UV-2075 absorbance detector.   
For the ultrafiltration-based binding studies, each mixture of tolbutamide and 
HSA or glycated HSA was incubated at 37ºC for 45 min; the use of longer incubation 
times (i.e., up to 90 min) did not produce any significant change in the final results. Prior 
to ultrafiltration, the membrane in each Centrifree ultrafiltration device was rinsed three 
times with water and pH 7.4, 0.067 M potassium phosphate buffer to reduce interferences 
by any contaminants or preservatives that may have been present in the device.  The 
ultrafiltration device was spun for at least 15 min at 1,500  g after rinsing to avoid 
dilution errors due to the presence of any remaining rinse solution in the device; the 
volume of rinse solution that remained after this step was less than 10 L.  The 
ultrafiltration experiments were carried out by placing 1 mL of each drug/protein mixture 
into the ultrafiltration device and spinning this mixture at 1,500  g for 25 min at 37 ºC.  
The filtrate was collected and analyzed for its drug content by making triplicate 5 L 
injections onto a flow-injection analysis system at 0.5 mL/min and in the presence of pH 
7.4, 0.067 M potassium phosphate buffer.  The elution of tolbutamide was monitored at 
227 nm.  A correction for any contaminants or preservatives remaining in the filtrate was 
made by carrying out similar measurements on filtrates for 0.5 mL samples that contained 
only glycated HSA in pH 7.4, 0.067 M potassium phosphate buffer.  
Notes on other experimental methods.  In the bicinchoninic acid (BCA) protein 
assay that was performed to determine the protein content of each HSA/glycated HSA 
support, there was no measureable difference in the response for standards based on 
normal HSA versus glycated HSA in this assay.  Although sulfonylurea drugs are weak 
acids with pKa values of 5.2-6.2, a change in pH of less than 0.05 units was seen in the 
pH 7.4 buffer when these drugs were present even at the highest concentrations that were 
utilized in the frontal analysis and zonal elution experiments. 
In the frontal analysis studies shown in Figure 2, the relative standard deviations 
for the measured binding capacities ranged from only  0.01% to  5.5% (average,  
1.1%) for triplicate measurements at the sixteen tested drug concentrations.  Similar 
precisions were obtained for the other columns and drugs that were examined in this 
study.  The zonal elution results in Figure 3(a-b) gave retention factors with relative 
standard deviations that ranged from  0.08% to  0.93% (average,  0.24%) and  
0.60% to  5.0% (average,  1.9%) for triplicate injections of R-warfarin or L-tryptophan 
as the injected probe, respectively, and over seven concentrations of tolbutamide or 
acetohexamide in the mobile phase for the in vivo glycated HSA columns.  Similar 
precisions were again obtained with the other drugs that were examined. 
Analysis of glycation products and glycation patterns. Both qualitative and 
quantitative studies based on MALDI–TOF-MS were used to examine the types and 
levels of modification that occurred for the in vivo glycated HSA, as based on methods 
described in Refs. 1s-4s.  The results are summarized in Tables 1s and 2s for clinical 
sample HSA-CS1.  These data include the regions of the in vivo glycated HSA that were 
found to be glycated, as well as the suspected residues at which these regions were 
modified and the types of modifications which may have been present.  
The data in Tables 1s and 2s show that there were several modifications in this 
sample of in vivo glycated HSA that occurred at or near Sudlow sites I and II.
1s-5s
  
Regions that were found to be modified and that occurred around these sites included 
residues 160-181, 189-208, 196-212, 275-286 and 286-297, all of which were located 
within Sudlow Site I. In addition, residues 359-376, 415-436 and 476-500 are located at 
or near Sudlow site II and were also found to be modified during in vivo glycation.  These 
results agree with those seen in this report for the binding studies using the same 
preparation of in vivo glycated HSA, in which shifts in affinity were noted for several of 
the sulfonylurea drugs at Sudlow sites I and II when comparing this protein preparation to 
normal HSA. 
Table 1s summarizes the results of quantitative studies that made of use of 
MALDI-TOF-MS and 
16
O/
18
O-labeling with the in vivo glycated HSA.  In this case, 
peptides from residues 5-20, 7-17, 94-106, 275-286 and 286-297, among others, were 
found to be modified and have elevated 
16
O/
18
O ratios versus control samples that were 
prepared using normal HSA. These regions exhibited considerable overlap with the 
regions of modification that were previously seen for in vitro glycated HSA samples that 
were prepared under similar conditions and used in the binding studies described in Refs. 
25-27 (as cited in the main body of the text).     
The glycation products formed on the in vivo glycated HSA were identified by 
determining the peptide ions with mass values that were unique to the in vivo glycated 
HSA samples.
3s,4s
  The corresponding modifications were then determined by comparing 
these masses with a theoretical list of modified peptides that might result from a glycated 
HSA digest. When this approach was used, several early and late-stage glycation adducts 
were assigned to the in vivo glycated HSA sample, as listed in Table 2s.  For this sample, 
18 peptides were found to be modified to form a mixture of early glycation products and 
AGEs.  Seven of those modified peptides were also found to be modified in prior work 
that used preparations of in vitro glycated HSA, with another two regions showing 
significant areas of overlap. For example, modifications were found in regions 189-208, 
275-292, 312-321 and 542-585 for both the in vivo glycated HSA and previously-
examined samples of in vitro glycated HSA.
1s-4s
    
Two different peptides (K190/K199) were found to be modified on the in vivo 
glycated HSA to produce CML and LL (see list of abbreviations and full names for these 
products that are provided in Tables 1s and 2s); previous studies using in vitro glycated 
HSA with various stages of glycation showed modifications assigned to K199 due to FL 
at early stages of glycation and due to Pyr during later stages of glycation.
2s,4s
 These 
results corroborate that K199 is prone to both in vivo and in vitro glycation, in agreement 
with various reports that have found K199 to be a major glycation site on HSA.
1s-4s,6s
 In 
addition, K276 and K281 within residues 275-286 were found to be modified to form two 
Pyr or C2-CML+AL in the in vivo glycated HSA. In previous studies using in vitro 
samples, K281 was modified to form FL-related modifications such as FL-1H2O/FL-
2H2O, as well as CEL and/or Pyr.
4s
  This information is consistent with other reports that 
have denoted K281 as another major modification site in glycated HSA.
3s,6s 
 Within the 
region 5-20, two peptides (R10/K12) were found to be modified during in vivo glycation 
to produce a FL/G-H1 precursor or CML+3,4-dihydroxy-2-imidazoline.  This same 
region was found to be modified to form FL on K12 when using an in vitro glycated HSA 
sample in Ref. 4s. 
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Table 1s. Glycation versus control (G/C) indices obtained through 
16
O/
18
O- labeling 
and MALDI-TOF-MS and indicating the presence of an increase in 
glycation-related modifications for in vivo glycated HSA versus normal 
HSA as a control
1s,2s 
 Residues (Digest) 
Modification 
site   
Potential adducts
a
 G/C Index
b
 
275-286 (Trypsin) K276/K281  CML & Pyr/Pyr 1.9 (± 0.2) 
557-565 (Glu-C) 
561-574 (Trypsin) 
K564 
FL/AFGP & 
FL/CML 
1.7 (± 0.2)
c
  
286-297 (Glu-C)  
274-286 (Trypsin) 
K286 AFGP 1.9 (± 0.2)
c
 
566-585 (Glu-C)  
561-574 (Trypsin) 
K573/K574 FL/CML & FL/FL 1.7 (± 0.2)
c
 
94-106 (Lys-C) R98 G-H1 2.0 (± 0.1)   
5-20 (Lys-C) 
7-17 (Glu-C) 
R10/K12 
FL/G-H1 precursor;  
CML/3,4-dihydroxy-
2-imidazoline 
1.3 (± 0.1)
d
  
476-500 (Lys-C) 
480-492 (Glu-C) 
R484/R485 ArgP/MG-H1 1.8 (± 0.1)
d
 
 
a
Abbreviations: AFGP, 1-alkyl-2-formyl-3,4-glycol-pyrole; ArgP, argpyrimidine; CML, 
N -carboxymethyl-lysine; FL, fructosyl-lysine; G-H1, hydroimidazolone derived from 
glyoxal, or Nε-(5-hydro-4-imidazolon-2-yl)ornithine;  MG-H1, hydroimidazolone derived 
from methylglyoxal, or Nε-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine; Pyr, 
pyrraline. 
b
The values in parentheses represent ± 1 standard error of the mean.  
c
This result was obtained for the tryptic digest.  The result for K286 is the value obtained 
for residues 275-286. 
d
This result was obtained for the Glu-C digest. 
Table 2s. Suspected modification sites found in various digests of in vivo glycated 
HSA 
 
Residues (digest) 
 
Suspected sites (modification)
a
 
 
  
275-286 (Trypsin) 
 
 
 
K276 & K281 (Pyr+Pyr)  
K276 & K281 (C2-CML+AL) 
 
 
415-436 (Trypsin) 
 
 
K432 (FL-H2O) & R428 (oxMG-H1) 
 
 
542-560 (Trypsin) 
 
 
K545 & K557 (Pyr+AL) 
 
 
189-208 (Glu-C) 
 
 
K190 & K199 (CML+LL) 
 
 
278-292 (Glu-C) 
 
 
K281 & K286 (AL+AL) 
 
 
312-321 (Glu-C) 
 
 
K313 or K317 (CML);  
K313 & K317 (FL-2H2O+AFGP) 
 
359-376 (Glu-C) 
 
 
K372 (FL-1H2O) 
 
 
566-585 (Glu-C) 
 
 
K573/K574 (FL-1H2O+C2-CML  
or CML+FL-2H2O; FL+FL) 
 
557-565 (Glu-C) 
 
 
K557, K560 or K564 (FL-1H2O+AFGP) 
 
 
557-571 (Glu-C) 
 
 
K560 & K564 (FL+CML) 
 
 
5-20 (Lys) 
 
 
 
R10 & K12 (FL+C2-G-H1 or  
CML+3,4-dihydroxy-2-imidazoline) 
 
94-106 (Lys) 
 
 
 
R98 (G-H1) 
 
 
160-181 (Lys) 
 
 
 
 
K162 & K174 or R160 & K162/K174 (Pyr+Pyr; CEL+FL-
1H2O; FL+MG-H1; CEL+3-DG-H1; CEL+THP) 
 
160-174 (Lys) 
R160 & K162 (AFGP+MG-H1 or 
 
FL+3,4-dihydroxy-2-imidazoline) 
 
 
196-212 (Lys) 
K199/K205 & R197/R209 (C2-CML+oxMG-H1 or 
 
G-H1+oxMG-H1) 
 
 
476-500 (Lys) 
 
R484 & R485 (ArgP+oxMG-H1) 
 
 
a
Abbreviations: AFGP, 1-alkyl-2-formyl-3,4-glycol-pyrole; AL, allysine; ArgP, 
argpyrimidine; C2-CML, N -carboxymethyl-lysine precursor (C2-imine); C2-G-H1, 
precursor for hydroimidazolone derived from glyoxal (C2-imine); CEL, Nε-carboxyethyl-
lysine; 3-DG-H1, hydroimidazolone derived from 3-deoxyglucosone; CML, N -
carboxymethyl-lysine; FL, fructosyl-lysine; FL-xH2O, dehydrated fructosyl-lysine;  G-
H1, hydroimidazolone derived from glyoxal, or Nε-(5-hydro-4-imidazolon-2-yl)ornithine; 
LL, 3-(N'-lysino)-lactic acid; MG-H1, ; oxMG-H1, oxidized Nε-(5-hydro-5-methyl-4-
imidazolon-2-yl)ornithine; Pyr, pyrraline; THP, tetrahydropyrimidine. 
 
  
Figure Legends 
Figure 1s. Typical chromatograms obtained at 0.5 mL/min by carrying out frontal 
analysis on an affinity microcolumn containing glycated HSA-clinical 
sample 2 (glycated HSA-CS2) and using solutions that contained 1.0, 2.5 
or 5.0 M acetohexamide (bottom-to-top).  Other conditions are given in 
the text. 
 
Figure 2s. Fit of frontal analysis data obtained for acetohexamide on the glycated 
HSA-CS1 column when using a one-site model, as described by eq (1s).
7s
  
Each data point represents the average of three measurements for mLapp, 
the moles of analyte required to reach the mean point of the breakthrough 
curve at a given molar concentration of the applied analyte.  The error bars 
represent ± 1 S.D. for this value and ranged in size from ± 0.01-5.5% 
(average, ± 1.1%).  Terms: molar concentration of applied analyte A, [A]; 
Ka1 and Ka2, association equilibrium constants for the analyte at binding 
sites 1 and 2; mL1 and mL2, total moles of binding sites 1 and 2 in the 
column. 
                        
                                             
 
Figure 3s. Zonal elution results were generated at 0.5 mL/min on the glycated HSA 
clinical sample 1 column (glycated HSA-CS1) by using 5 M R-warfarin 
as the injected probe and mobile phases that contained 0, 1, 5, 10, 15 or 20 
M acetohexamide (bottom-to-top).  Other conditions are given in the text.  
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